Richard Sykes Net Worth

Richard Sykes biography

Sir Richard Sykes Ph.D. serves as Independent Director of the Company. Sir Richard Sykes has served on PDS’s board of directors since December 2014. He is currently Chairman of Imperial College Healthcare King Edward V11 Hospital, Chairman of the Royal Institution of Great Britain, Chairman of the UK Stem Cell Foundation, Chairman of Omnicyte. He was appointed Chancellor of Brunel University in 2013. Prior to that, he was Senior Independent Director and non-executive Chairman of ENRC from 2007 to June 2011, Chairman of NHS London from December 2008 to July 2010, Rector of Imperial College London from 2000 to 2008. He was a non-executive director of Rio Tinto plc from 1997 to 2007, and senior independent director from 2004 to 2007. He has over 30 years’ experience within the biotechnology and pharmaceutical industries field, serving as Chief Executive and Chairman of GlaxoWellcome from 1995 to 2000 and then as Chairman of GlaxoSmithkline until 2002. Internationally he is Chairman of the International Advisory Board, A*Star Biomedical Research Council, Singapore and a Board member of EDBI. He was awarded Honorary Citizenship of Singapore in 2004 for his contribution to the development of the country’s biomedical sciences industry. Sir Richard holds a number of degrees and awards from Institutions both in the UK and overseas. He is a Fellow of the Royal Society and Academy of Medical Sciences, and an Honorary Fellow of the Royal Academy of Engineering, Royal Society of Chemistry, Royal Pharmaceutical Society, Royal College of Pathologists and the Royal College of Physicians. He is also President of the R and D Society, a position he has held since 2002. He is a Fellow of Imperial College London and the Imperial College School of Medicine, King’s College London and Honorary Fellow of the Universities of Wales and Central Lancashire. Sir Richard received a Knighthood in the 1994 New Year’s Honours list for services to the pharmaceutical industry.

What is the salary of Richard Sykes?

As the Independent Director of PDS Biotechnology, the total compensation of Richard Sykes at PDS Biotechnology is $78,642. There are 8 executives at PDS Biotechnology getting paid more, with Frank Bedu-Addo having the highest compensation of $2,583,760.

How old is Richard Sykes?

Richard Sykes is 78, he's been the Independent Director of PDS Biotechnology since 2019. There are no older and 14 younger executives at PDS Biotechnology.

What's Richard Sykes's mailing address?

Richard's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540.

Insiders trading at PDS Biotechnology

Over the last 5 years, insiders at PDS Biotechnology have traded over $0 worth of PDS Biotechnology stock and bought 54,275 units worth $476,657 . The most active insiders traders include Gregory Gene Freitag, James J Loughlin, eKamil Ali Jackson. On average, PDS Biotechnology executives and independent directors trade stock every 67 days with the average trade being worth of $126,706. The most recent stock trade was executed by Frank Bedu Addo on 2 December 2022, trading 219,535 units of PDSB stock currently worth $1,442,345.

What does PDS Biotechnology do?

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati

PDS Biotechnology executives and stock owners

PDS Biotechnology executives and other stock owners filed with the SEC include:

• Frank Bedu-Addo,
  President, Chief Executive Officer, Director
• Dr. Frank K. Bedu-Addo Ph.D.,
  Pres, CEO & Director
• Gregory Conn,
  Chief Scientific Officer
• Lauren V. Wood M.D.,
  Chief Medical Officer
• Dr. Gregory L. Conn,
  Chief Scientific Officer
• Gregory Freitag,
  Independent Director
• DeLyle Bloomquist,
  Independent Director
• Stephen Glover,
  Independent Chairman of the Board
• Richard Sykes,
  Independent Director
• Otis Brawley,
  Director
• Deanne Randolph,
  Investor Relations
• Kamil Ali-Jackson,
  Independent Director
• Ilian Iliev,
  Director
• Lauren Wood,
  Chief Medical Officer
• Michael King,
  Interim Chief Financial Officer
• Janetta Trochimiuk,
  Controller
• Dr. Mark Baxter Ph.D.,
  Sr. VP of Global Quality
• Hillary Yegen,
  VP of Legal
• Dr. Joe J. Dervan,
  VP of R&D
• Matthew C. Hill CPA,
  CFO & Principal Accounting Officer
• Matthew C Hill,
  Chief Financial Officer
• James J Loughlin,
  Director
• Voorhees Seth Van,
  Chief Financial Officer
• Lars Boesgaard,
  Chief Financial Officer
• Spencer D. Brown,
  Senior VP, General Counsel
• Kirk V. Shepard,
  Chief Medical Officer
• Stephan Toutain,
  Chief Operations Officer